Observations that make me uncomfortable, page-17

To skip to a paragraph of the conclusion of the previous research paper:

"Few HA-drug delivery systems are yet in clinical trials. Several points must be studied and understood in depth in order to design and improve the efficacy of systems based on CD44 targeting. It is clear that several parameters, such as HA’s molecular weight, the site and degree of chemical modifications, its size and surface characteristics, can all significantly affect the interaction of HA-modified system with the target, avoiding preferential uptake by the reticuloendothelial system. In particular, in authors opinion the chemical conjugation strategies play a crucial role in the preparation, stability, in vitro and in vivo activity of HA-based conjugates. Further research into these and other parameters offer promising prospects for interesting new developments in this field."

I hope that we are one of the first of these new developments in this field.